- ►annals.org [PDF] M Tonelli, L Moye, FM Sacks, B Kiberd, G … - Annals of internal medicine, 2003 - Am Coll Physicians Background: Cardiovascular disease is a common cause of mor- bidity and death in
persons with renal insufficiency. Although 3-hydroxy-3methylglutaryl coenzyme A
reductase inhibitors (statins) are effective for secondary prevention of ... Cited by 108 - Related articles - BL Direct - All 8 versions
- ►asnjournals.org M Tonelli, L Moye, FM Sacks, T Cole, GC … - Journal of the American Society of Nephrology, 2003 - Am Soc Nephrol Hyperlipidemia has been hypothesized to play an important role in the
progression of renal insufficiency, either through toxic effects of lipids on
mesangial cells or by promoting intrarenal atherosclerosis (8–10). In ... Cited by 126 - Related articles - BL Direct - All 7 versions
Y Imai, H Suzuki, T Saito, I Tsuji, K Abe, T … - Clinical and Experimental Hypertension, 1999 - informahealthcare.com Page 1. Page 2. Page 3. Page 4. Page 5. Page 6. Page
7. Page 8. Page 9. Page 10. Page 11.
Cited by 24 - Related articles - BL Direct - All 4 versions
SL Seliger, NS Weiss, DL Gillen, B … - Kidney international, 2002 - nature.com Patients with end-stage renal disease (ESRD) suffer from markedly higher rates
of cardiovascular disease than the general population. Although therapy with
3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors ... Cited by 202 - Related articles - BL Direct - All 5 versions
OA Gheith, MAK Sobh, KES Mohamed, M El- … - Nephron, 2000 - content.karger.com In this study 43 patients with idiopathic nephrotic syndrome were randomly
distributed into 2 age- and sex-matched groups. The first group was given
fluvastatin while the second was used as control. The cases in the 2 groups ... Cited by 24 - Related articles - BL Direct - All 6 versions
MW Taal, BM Brenner - Current opinion in nephrology and hypertension, 2001 - journals.lww.com Experimental and clinical studies over the past two decades have identified
several interventions for slowing the progression of chronic renal disease
towards end-stage renal failure. In this paper we review the experimental ... Cited by 24 - Related articles - BL Direct - All 7 versions
- ►oxfordjournals.org MA van Dijk, AM Kamper, S van Veen, JHM … - Nephrology Dialysis Transplantation, 2001 - ERA-EDTA Results. After treatment with simvastatin, glomerular filtration rate (GFR)
significantly increased from 124±4 ml/min to 132±6 ml/min (P<0.05).
Simultaneously, effective renal plasma flow (ERPF) increased significantly ... Cited by 38 - Related articles - BL Direct - All 4 versions
C Baigent, M Landry - Kidney International, 2003 - nature.com There are several reasons why the demonstrated benefits of lowering blood
cholesterol in other populations might not translate to patients with CKD.
First, observational studies among dialysis patients have reported a ... Cited by 194 - Related articles - All 4 versions
KPG Harris, DC Wheeler, CC Chong - Kidney international, 2002 - nature.com 1 The Atorvastatin in CAPD Study investigators who were involved in the study
include: P. Ackrill (Manchester); RA Banks (Gloucester); L. Barker (Reading); JM
Boulton (Glasgow); E. Brown (London); H. Cairns (London); P. Conlon ... Cited by 35 - Related articles - BL Direct - All 5 versions
T Nakamura, C Ushiyama, K Hirokawa, S … - American journal of nephrology, 2000 - content.karger.com Background/Aims: To determine whether cerivastatin, a newly developed novel
synthetic potent statin, exerts a renoprotective effect, we assessed urinary
albumin excretion (UAE) and plasma and urinary endothelin (ET)-1 ... Cited by 51 - Related articles - BL Direct - All 5 versions
